Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases

被引：23

作者：

Erra, Montse ^{[1
]}

Taltavull, Joan ^{[1
]}

Greco, Angelique ^{[1
,5
]}

Javier Bernal, Francisco ^{[1
]}

Francisco Caturla, Juan ^{[1
]}

Gracia, Jordi ^{[1
]}

Dominguez, Maria ^{[2
]}

Sabate, Mar ^{[2
]}

Paris, Stephane ^{[1
]}

Soria, Salome ^{[1
]}

Hernandez, Begona ^{[1
,7
]}

Armengol, Clara

Cabedo, Judit ^{[3
,4
]}

Bravo, Monica ^{[4
]}

Calama, Elena ^{[4
]}

Miralpeix, Montserrat ^{[4
]}

Lehner, Martin D. ^{[4
,6
]}

机构：

[1] Almirall R&D, Med Chem & Screening, Barcelona 08980, Spain

[2] Almirall R&D, Pharmacokinet & Metab, Barcelona 08980, Spain

[3] Almirall R&D, Syst Biol, Barcelona 08980, Spain

[4] Almirall R&D, Resp Therapeut Area, Barcelona 08980, Spain

[5] Pharmaxis Ltd, 20 Rodborough Rd, Frenchs Forest, NSW 2086, Australia

[6] Bionor SE, Kerschensteinerstr 11-15, D-92318 Neumarkt, Germany

[7] Fundacio ACE, Marques Sentmenat,57, Barcelona 08029, Spain

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2017年 / 8卷 / 01期

关键词：

Phosphoinositide-3-kinase delta inhibitor; PI3K delta inhibitor; structure-activity relationship; autoimmune diseases; inflammatory diseases; lead optimization; PHOSPHOINOSITIDE 3-KINASE DELTA; IMMUNE-RESPONSES; P110-DELTA; IDELALISIB; AUTOIMMUNE; BINDING; MICE;

D O I：

10.1021/acsmedchemlett.6b00438

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The delta isoform of the phosphatidylinositol 3-kinase (PI3K delta) has been shown to have an essential role in specific immune cell functions and thus represents a potential therapeutic target for autoimmune and inflammatory diseases. Herein, the optimization of a series of pyrrolotriazinones as potent and selective PI3K delta inhibitors is described. The main challenge of the optimization process was to identify an orally available compound with a good pharmacokinetic profile in preclinical species that predicted a suitable dosing regimen in humans. Structure activity relationships and structure property relationships are discussed. This medicinal chemistry exercise led to the identification of LAS191954 as a candidate for clinical development.

引用

页码：118 / 123

页数：6

共 50 条

[41] Discovery of Novel Indazoles as Potent and Selective PI3Kδ Inhibitors with High Efficacy for Treatment of Hepatocellular Carcinoma
Qi, Jifeng
Wang, Weihua
Tang, Yongmei
Lou, Shengying
Wang, Jiaer
Yuan, Tao
He, Qiaojun
Yang, Bo
Zhu, Hong
Cui, Sunliang
JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (05) : 3849 - 3865
[42] In vitro profiling of the potent and selective PI3K inhibitor AEZS-126
Seipelt, Irene
Gerlach, Matthias
Blumenstein, Lars
Mueller, Gilbert
Teifel, Michael
Polymeropoulos, Emmanuel
Guenther, Eckhard
CANCER RESEARCH, 2009, 69
[43] Discovery of an irreversible PI3Kα-specific Inhibitor
Qiao, Lixin
Nacht, Mariana
Sheets, Michael P.
St Martin, Thia
Labenski, Matthew
Mazdiyasni, Hormoz
Zhu, Zhendong
Chaturvedi, Prasoon
Bhavsar, Deepa
Niu, Deqiang
Westlin, William
Petter, Russell
Singh, Juswinder
CANCER RESEARCH, 2011, 71
[44] In vitro characterization of AMG 511, a potent and selective class I PI3K inhibitor for the treatment of cancer
Caenepeel, Sean
Zhang, Nancy
Wang, Ling
Norman, Mark H.
Burgess, Terri
Radinsky, Robert
Kendall, Rick
Freeman, Daniel
Hughes, Paul E.
CANCER RESEARCH, 2012, 72
[45] Identification of GSK2636771, a potent and selective, orally bioavailable inhibitor of phosphatidylinositol 3-kinase-beta (PI3Kα) for the treatment of PTEN deficient tumors
Rivero, Ralph A.
Hardwicke, Mary Ann
CANCER RESEARCH, 2012, 72
[46] Discovery and antiplatelet activity of a selective PI3Kβ inhibitor (MIPS-9922)
Zheng, Zhaohua
Pinson, Jo-Anne
Mountford, Simon J.
Orive, Stephanie
Schoenwaelder, Simone M.
Shackleford, David
Powell, Andrew
Nelson, Erin M.
Hamilton, Justin R.
Jackson, Shaun P.
Jennings, Ian G.
Thompson, Philip E.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 122 : 339 - 351
[47] Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndrome
Rao, V. Koneti
Kulm, Elaine
Grossman, Jennifer
Buchbinder, David
Chong, Hey
Bradt, Jason
Webster, Sharon
Sediva, Anna
Dalm, Virgil A.
Uzel, Gulbu
BLOOD ADVANCES, 2024, 8 (12) : 3092 - 3108
[48] Discovery of a Novel Series of Potent and Selective Alkynylthiazole-Derived PI3Kγ Inhibitors
Bandarage, Upul K.
Aronov, Alex M.
Cao, Jingrong
Come, Jon H.
Cottrell, Kevin M.
Davies, Robert J.
Giroux, Simon
Jacobs, Marc
Mahajan, Sudipta
Messersmith, David
Moody, Cameron S.
Swett, Rebecca
Xu, Jinwang
ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (01): : 129 - 135
[49] Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer
Wu, Zhengyang
Bai, Ying
Jin, Jiaming
Jiang, Teng
Shen, Hui
Ju, Qiurong
Zhu, Qihua
Xu, Yungen
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 217
[50] Discovery and characterization of OKI-219, an orally bioavailable H1047R-mutant-selective inhibitor of PI3Kα
Taylor, Molly A.
Zhao, Qian
Mareska, David
Hoh, Maria
Izrayelit, Yevgeniy
Litwiler, Kevin
Boys, Mark L.
Woessner, Rich
Walker, Duncan
Diamond, Jennifer
Winkler, James D.
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)

← 1 2 3 4 5 →